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Abstract
Background: Mounting evidence suggests a role for the gut microbiota in modulating brain physiology and
behaviour, through bi-directional communication, along the gut-brain axis. As such, the gut microbiota represents a
potential therapeutic target for influencing centrally mediated events and host behaviour. It is thus notable that the
fermented milk beverage kefir has recently been shown to modulate the composition of the gut microbiota in
mice. It is unclear whether kefirs have differential effects on microbiota-gut-brain axis and whether they can
modulate host behaviour per se.
Methods: To address this, two distinct kefirs (Fr1 and UK4), or unfermented milk control, were administered to
mice that underwent a battery of tests to characterise their behavioural phenotype. In addition, shotgun
metagenomic sequencing of ileal, caecal and faecal matter was performed, as was faecal metabolome analysis.
Finally, systemic immunity measures and gut serotonin levels were assessed. Statistical analyses were performed by
ANOVA followed by Dunnett's post hoc test or Kruskal-Wallis test followed by Mann-Whitney U test.
Results: Fr1 ameliorated the stress-induced decrease in serotonergic signalling in the colon and reward-seeking
behaviour in the saccharin preference test. On the other hand, UK4 decreased repetitive behaviour and ameliorated
stress-induced deficits in reward-seeking behaviour. Furthermore, UK4 increased fear-dependent contextual
memory, yet decreased milk gavage-induced improvements in long-term spatial learning. In the peripheral immune
system, UK4 increased the prevalence of Treg cells and interleukin 10 levels, whereas Fr1 ameliorated the milk
gavage stress-induced elevation in neutrophil levels and CXCL1 levels. Analysis of the gut microbiota revealed that
both kefirs significantly changed the composition and functional capacity of the host microbiota, where specific
bacterial species were changed in a kefir-dependent manner. Furthermore, both kefirs increased the capacity of the
gut microbiota to produce GABA, which was linked to an increased prevalence in Lactobacillus reuteri.
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Conclusions: Altogether, these data show that kefir can signal through the microbiota-gut-immune-brain axis and
modulate host behaviour. In addition, different kefirs may direct the microbiota toward distinct immunological and
behavioural modulatory effects. These results indicate that kefir can positively modulate specific aspects of the
microbiota-gut-brain axis and support the broadening of the definition of psychobiotic to include kefir fermented
foods.
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Introduction
Mounting evidence suggests that the gastrointestinal
microbiota influences host behaviour via bi-directional
communication through what has been coined the
microbiota-gut-brain axis [17, 18, 20, 29, 50, 60, 71].
Various nutritional interventions have already been
demonstrated to influence this axis, with host-
indigestible dietary fibres (prebiotics) and live bacterial
strains that confer health benefits (probiotics) receiving
particular attention [20, 38, 48]. Such interventions that
modulate mood through manipulation of the microbiota
have been coined psychobiotics [24]. It is becoming ap-
parent that fermented foods may also confer beneficial
effects on aspects of mood, as fermented food intake is
associated with decreased social anxiety [33] and gesta-
tional depression in humans [51]. In addition, a fermen-
ted milk product, which was produced using known
probiotics, has been demonstrated to modulate brain ac-
tivity in healthy women [82]. Such findings merit an in-
vestigation into the mechanisms by which different
fermented foods might affect the microbiota-gut-brain
axis.
One such fermented foods are kefir, a traditional fer-
mented milk beverage originating from the Caucasus
mountains that is produced by adding a kefir grain to
milk. These grains consist of exopolysaccharide matrices
harbouring symbiotic microbial communities, including
bacteria and yeasts, which together are responsible for
fermentation [12]. Notably, the word kefir is derived
from the Turkish keyif, which translates as “good feel-
ing”. Indeed, numerous health benefits have been as-
cribed to kefir [62, 75], such as anti-inflammatory effects
in animal models [41, 47, 61], reduced obesity symptom-
atology in high fat diet-induced obese mice [11, 30, 40],
and reduced hypertension in spontaneously hypertensive
rats [73]. Furthermore, kefir administration has been
shown to reduce physical fatigue and improve exercise
performance in mice [34]. A recent randomised, con-
trolled trial has even shown that kefir can reduce bloat-
ing and improve mood in patients with inflammatory
bowel disease [90]. Finally, kefir has been shown to
modulate the composition of the gastrointestinal micro-
biota in rodents [11, 30, 34, 40]. Overall, current evi-
dence indicates that the traditionally fermented milk
drink kefir merits investigation to determine its ability to
modulate the microbiota-gut-brain axis and affect the
mood of the host. It is not clear if kefir’s exert differen-
tial influence across the microbiota-gut-brain axis due to
their compositional differences [12]. As such, we investi-
gated if two different kefirs could affect the microbiota
of ileal, caecal and faecal contents, the faecal metabo-
lome, gastrointestinal function, host adaptive and innate
immunity, and behaviour in mice.
Results
Kefir microbiota was relatively stable over time
The milk kefir used in this study was generated in a
manner to represent traditional kefir production (i.e., re-
peated fermentation of milk by a kefir grain). Consider-
ing that kefir contains a complex microbiota community
composed of a variety of strains [12], we determined if
this community remained stable over time. Shotgun
metagenomics was used to determine the species-level
composition of the two kefirs, Fr1 and UK4, at 6 time-
points at intervals of 2 weeks throughout the in vivo
study. Overall, the populations were generally temporally
stable, with both kefirs being dominated by Lactococcus
lactis, while also consistently containing L. kefiranofa-
ciens (Figure S1). Several other species were identified at
specific time-points at > 1% relative abundance in both
kefirs, such as Bifidobacterium breve and Pseudomonas
species. Notably, L. kefiranofaciens was more abundant
in kefir Fr1 at some time points.
The fermented milk drink kefir is well-tolerated
Kefir administration did not affect body weight, body com-
position, food intake and drinking water intake (Figure S2).
In addition, no differences were found in basal body
temperature, as detected in the stress-induced hyperther-
mia test, as well as locomotor activity assessed in the open
field test (Figure S2). Overall, this indicates that the fermen-
ted milk drink kefir was well-tolerated by mice.
Kefir did not affect measures of gastrointestinal
physiology and motility
Assessment of gastrointestinal motility by carmine red
administration showed that kefir did not induce any
changes in gastrointestinal propulsion (Figure S3). In
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line with these findings was the absence of differences in
faecal pellet weight and faecal water content (Figure S3).
Finally, no differences in caecum weight and colon
length were detected at the end of the study (Figure S3).
Overall, these data indicate that changes in the gut
microbiota are likely independent of host gastrointestinal
physiology and motility.
Kefir modulates repetitive behaviour and reward-seeking
behaviour
In the marble burying test, we found that administration
of UK4 decreased the number of marbles buried indica-
tive of reduced repetitive behaviour (F(2,35) = 5.464, p =
0.009) (Fig. 1a). No changes were observed in tests asses-
sing anxiety-like behaviours such as the elevated plus
maze, open field test and stress-induced hyperthermia
test (Figure S4), as well as depressive-like behaviour in
the forced swim test and tail-suspension test (Figure S4).
Notably, repeated stress of milk gavage increased the
corticosterone response to an acute stressor, which
remained unaffected by kefir (Figure S4).
In the female urine sniffing test of reward-seeking,
mice receiving milk spent less time interacting with the
cotton bulb containing water compared to undisturbed
mice (χ2(1) = 6.367, p = 0.012), which was ameliorated
by both Fr1 and UK4 (χ2(2) = 13.238, p < 0.001) (Fig.
1b). In addition, mice receiving UK4 spent more time
interacting with the cotton bulb containing the urine
from a female mouse in esterus (χ2(2) = 6.280, p =
0.043) (Fig. 1b), even though no differences were
observed in the preference index (Fig. 1c). Finally, Fr1
administration increased saccharin preference in the sac-
charin preference test (χ2(2) = 12.826, p = 0.002), which
is often used as a measure of reward-seeking behaviour
(Fig. 1d, e).
Kefir does not affect sociability
All groups exhibited normal social preference and recog-
nition in the 3-chamber social interaction test, indicating
that kefir did not affect sociability (Figure S5).
Kefir–UK4 modulates contextual learning and memory
No differences were observed in the fear conditioning
test in phase 1—acquisition, as determined by the time
mice spent frozen during the presentation of the cue, as
well as in-between the cues (Fig. 2a, b). In addition, no
differences were seen during phase 2, when cued-
dependent fear memory was assessed (Fig. 2c). However,
mice receiving UK4 showed a trend towards increased
freezing behaviour in phase 3—contextual memory (F(2,
34) = 3.181, p = 0.055) (Fig. 2d). Conversely, mice re-
ceiving UK4 made more errors in the reverse learning
phase of the appetitive Y-maze as seen by the percentage
correct choices (treatment effect: F(2,33) = 3.870, p =
0.031) (Fig. 2e), and the amount of entries mice needed
to reach the food reward compared to milk control
(treatment effect: F(2,33) = 3.387, p = 0.046) (Fig. 2f).
Notably, a similar difference was found on day 10 in the
percentage correct choices made between the undis-
turbed control and Milk control group (t(22) = − 2.303,
Fig. 1 Kefir modulates repetitive behaviour and reward-seeking behaviour. Repetitive/anxiety-like behaviour was assessed using the marble
burying test (a). Anhedonia and reward-seeking behaviours were investigated using the female urine sniffing test (b, c) and saccharin preference
test (d, e). The marble burying test was normally distributed and analysed using a one-way ANOVA, followed by a Dunnett’s post hoc test. The
female urine sniffing test and saccharin preference test were non-normally distributed and analysed using the Kruskal-Wallis test, followed by the
Mann-Whitney test. Significant differences are depicted as *p < 0.05, **p < 0.01 and ***p <0.001; milk control compared to kefir supplementation,
$p < 0.05; undisturbed control compared to milk control. All data are expressed ‘as mean ± SEM (n = 11–12). Dots on each graph represent
individual animals
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p = 0.031), where the mice receiving milk control per-
formed superior to the undisturbed control (Fig. 2e).
Kefirs differentially impact the peripheral immune system
There was an increase in circulating LY6Chigh monocytes
in mice receiving milk, compared to undisturbed mice,
indicating an activation of the innate immune system
[32, 86]. Furthermore, there were increased levels of
various inflammatory cytokines in the peripheral circula-
tion (Figure S6). In line with this finding, was an in-
crease in neutrophil levels induced by milk
administration (t(22) = − 3.583, p = 0.002) (Fig. 3a),
which was ameliorated by Fr1 administration (F(2,34) =
5.412, p = 0.009) (Fig. 3a). Similarly, Fr1 ameliorated the
increased CXCL1 levels observed in mice chronically
stressed by milk gavage (t(21) = − 2.589, p = 0.017; F(2,
32) = 7.006, p = 0.003) (Fig. 3b), which is one of the
major chemoattractants for neutrophils [74].
UK4 increased the prevalence of T regulatory cells
(Treg) cells in mesenteric lymph nodes (MLNs) (F(2,34)
= 8.709, p < 0.001) (Fig. 3c), an anti-inflammatory T
helper cell subset known to be induced by gut microbial
metabolites [80]. These cells did not express the Helios
transcription factor (F(2,34) = 7.548, p = 0.002) (Fig. 3d).
This indicated that they were induced in the periphery
(pTreg) rather than in the thymus [72], suggesting that
gut microbial-derived metabolites could have driven this
increase in Treg cells. We subsequently investigated the
prevalence of MLN CD103+ dendritic cells, which are
known to induce Treg cell differentiation [79]. No corre-
sponding differences were found, as an increased preva-
lence of MLN CD103+ dendritic cells was observed in
the milk and kefir treatment groups, which is in line
with the increased levels of inflammatory cytokines in
the peripheral circulation (Figure S7). The effects of
UK4 also reached the peripheral circulation, where there
was an increased prevalence of Treg cells (F(2,31) =
3.420, p = 0.046) (Fig. 3e). Similarly, we observed in-
creased plasma IL-10 levels (F(2,32) = 6.205, p = 0.006)
(Fig. 3f), one of the primary cytokines secreted by Treg
cells [63].
Kefir–Fr1 selectively increases colonic serotonergic
activity
Serotonergic signalling is well-known to play a key-role
in microbiota-host cross-talk [55, 78], which is why we
quantified gut serotonin (5-HT) levels. We found that
mice receiving milk showed decreased ileal 5-HT levels
compared to undisturbed mice (t(21) = 2.650, p = 0.015)
(Fig. 4b). This resulted in an increased 5HIAA/5-HT
Fig. 2 UK4 enhances fear-dependent contextual memory yet decreases long-term spatial learning. Fear-dependent memory and learning were
assessed using fear conditioning. At phase 1—acquisition, mice were presented with a tone, followed by a foot shock. Cue-associative learning
was assessed by measuring freezing behaviour during the presentation of the tone (a), whereas context-associative learning was determined in-
between tones (b). At phase 2—cued memory, mice received 40 presentations of the same cue (the first 10 are shown), without foot shock, in a
different context, in which fear-dependent cued memory was assessed (c). At phase 3—contextual memory, mice were exposed to the same
context as day one for 5 min and contextual memory was assessed (d). Long-term spatial learning was assessed in the appetitive Y-maze, as
determined by the percentage of times the mice made the correct choice as the first choice for reaching the goal (food reward) (e), as well as
the number of average entries it took the mice to reach the goal (f). All data were normally distributed and analysed using a repeated measures
ANOVA or one-way ANOVA, followed by a Dunnett’s post hoc test. Significant differences are depicted as *p < 0.05; milk control compared to
kefir supplementation, $p < 0.05; undisturbed control compared to Milk control. All data are expressed as mean ± SEM (n = 10–12). Dots on each
graph represent individual animals
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ratio (t(22) = 2.650, p < 0.001) (Fig. 4c), indicating an in-
creased serotonin turnover and serotonergic activity. The
opposite was observed in the colon, where the milk in-
duced a trend towards increased 5-HT levels (t(22) = −
1.937, p = 0.066) (Fig. 4e), whilst decreasing the 5HIAA/5-
HT ratio (t(22) = 2.907, p = 0.008) (Fig. 4f). This pheno-
type in the colon, but not ileum, was ameliorated by Fr1
(for 5-HT; F(2,35) = 6.387, p = 0.005, for 5HIAA/5-HT ra-
tio; F(2,35) 9.026, p < 0.001) (Fig. 4e, f).
Both kefirs affect gut microbiota composition, at both the
species- and strain-levels
We subsequently investigated if kefir administration could
affect the composition of the ileal, caecal and faecal micro-
biota. Alpha diversity (Shannon) was not significantly
Fig. 3 UK4 increases Treg cells levels, while Fr1 decreases neutrophil levels. T regulatory cells (CD4+, CD25+, FoxP3+) were assessed in mesenteric
lymph nodes (MLNs) (a) and were subsequently analysed for Helios expression (b), to investigate their origin as Helios+ cells exclusively originate
in the thymus. Blood was also assessed for Treg cell levels (c), and plasma interleukin 10 (IL-10) levels (d). Similarly, neutrophil (CD11b+, LY6Cmid,
SSChigh and CXCL1 levels were also investigated in peripheral blood (e, f). All data were normally distributed and analysed using a one-way
ANOVA, followed by a Dunnett’s post hoc test. Significant differences are depicted as *p < 0.05, **p < 0.01; milk control compared to Kefir
supplementation, $p < 0.05 and $$p < 0.01; undisturbed control compared to milk control. All data are expressed as mean ± SEM (n = 11–12).
Dots on each graph represent individual animals
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altered by kefir Fr1 administration (Fr1; ileum p = 0.11;
caecum p = 0.19; faeces p = 0.16), whereas kefir UK4 in-
creased alpha diversity in the caecum (p = 0.017), but not
ileum and faeces (p = 0.44; p = 0.24) (Fig. 5a). Analysis of
beta diversity revealed a trend towards significant separ-
ation induced by the administration of Fr1 (ileum p =
0.088, R2 = 0.111; caecum p = 0.087, R2 = 0.087; faeces p =
0.077, R2 = 0.114) and UK4 (ileum p = 0.058, R2 = 0.092;
caecum p = 0.1, R2 = 0.092; faeces p = 0.073, R2 = 0.09)
(Fig. 5b). It is notable that, the kefir treatment overall did
influence beta diversity (p value ranged from 0.05 < p ≤
0.10 for all regions). Notably, no significant differences
were found between the administration of Fr1 and UK4 in
alpha diversity (ileum p = 0.37; caecum p = 0.34; faeces p
= 0.8) and beta diversity (ileum p = 0.316, R2 = 0.05; cae-
cum p = 0.14, R2 = 0.07; faeces p = 0.2, R2 = 0.062).
A total of 15 bacterial species were identified as be-
ing differentially abundant between at least one pair
of groups in at least one region of the gut (Fig. 5c).
Both kefirs increase the abundance in or more region
in the gut of Lactobacillus reuteri (Fr1, caecum LDA
= 4.36, UK4, caecum LDA = 4.02, UK4, faeces LDA
= 4.07), Eubacterium plexicaudatum (Fr1, faeces LDA
= 3.77, UK4, caecum: LDA = 4.22, UK4, faeces LDA
= 3.67), Bifidobacterium pseudolongum (Fr1, ileum
LDA = 4.93, UK4, caecum LDA = 4.7). Both kefirs
induced a decrease in the prevalence of Lachnospira-
ceae bacterium 3_1_46FAA (Fr1, caecum LDA = 4.25,
UK4 caecum: LDA = 4.28), Propionibacterium acnes
(Fr1, faeces LDA = 3.25, UK4, faeces, LDA = 4.04),
and Bacillus amyloliquefaciens (Fr1, faeces LDA =
3.04, UK4, faeces LDA = 3.58). Only Fr1 increased the
prevalence of Parabacteroides goldsteinii (caecum LDA =
3.99), Bacteroides intestinalis (faeces: LDA = 3.49), Anae-
rotruncus unclassified (faeces: LDA = 3.75), and Parabac-
teroides goldsteinii (faeces LDA = 4.02). Conversely, only
UK4 increased the prevalence of Alistipes unclassified
(caecum: LDA = 4.45) and decreased Candidatus Arthro-
mitus unclassified (ileum LDA = 4.45).
We subsequently correlated significantly altered be-
havioural and immunological parameters with bacterial
species present throughout the gastrointestinal micro-
biota (Fig. 6). Most notable was the correlation between
ileal C. Arthromitus unclassified abundances and circu-
lating Treg cell levels (p = 0.004, R = − 0.49), and ileal B.
pseudolongum abundances and circulating neutrophil
levels (p = 0.001, R = − 0.52).
PanPhlAn was used alongside StrainPhlAn to charac-
terise differentially abundant species to the strain-level.
Both tools indicated that the detected B. pseudolongum
strain was closely related to B. pseudolongum UMB-
MBP-01 (Figure S8). Similarly, PanPhlAn indicated
that the detected L. reuteri strain was closely related
to L. reuteri TD1. No other differentially abundant
species could be characterised to the strain-level. Fi-
nally, neither PanPhlAn nor StrainPhlAn identified
any kefir-derived strains in the gut microbiota of mice
receiving kefir, establishing that the microbiota of the
administered kefir did not colonise to high levels.
Fig. 4 Fr1 modulates serotonergic signalling in the colon, but not ileum. Ileal (a–c) and colonic (d–f) tissues were quantified for 5HIAA and
serotonin (5-HT) levels using HPLC. The 5HIAA/5-HT ratio was subsequently calculated. All data were normally distributed and analysed using a
one-way ANOVA, followed by a Dunnett’s post hoc test. Significant differences are depicted as: **p < 0.01; milk control compared to kefir
supplementation, $p < 0.05, $$p < 0.01 and $$$p < 0.001; Undisturbed control compared to milk control. All data are expressed as mean ± SEM (n
= 11–12). Dots on each graph represent individual animals
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Fig. 5 Kefir modulates the composition of the gastrointestinal microbiota. Alpha diversity (Shannon) of the ileal, caecal and faecal microbiota was
compared between mice receiving kefir (Fr1 or UK4) and mice receiving milk control using violin plots (a). Beta diversity was assessed by
PERMANOVA to investigate the dissimilarity in the gut microbial composition, which were depicted using MDS plots. Dots represent individual
animals (n = 12) (b). Differentially abundant taxa were determined using LEfSe (c)
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Kefir induces shifts in the functional potential of the gut
microbiome
We subsequently investigated if kefir administration could
affect the functional potential of the microbiome in mice.
Fr1 induced a significant functional separation in the
microbiome in the ileum (p = 0.052, R2 = 0.099) and the
caecum (p = 0.019, R2 = 0.079), but not in the faeces (p =
0.108, R2 = 0.068) (Fig. 7a). Similarly, UK4 induced a sig-
nificant functional separation in the caecum (p = 0.018, R2
= 0.092) and the faeces (p = 0.010, R2 = 0.09), but not in
the ileum (p = 0.212, R2 = 0.092) (Fig. 7a). No significant
functional separations were identified between any other
pair of groups in any other regions. The faecal metabo-
lome was assessed using GC-MS from a subset of animals
from each group (n = 6) to validate any changes observed
in the predicted functional potential of the gut micro-
biome (Table 3). Analysis of the beta diversity of the faecal
metabolome revealed a predominant effect of kefir Fr1 on
the measured metabolites (p = 0.045, R2 = 0.196). Notably,
no significant differences in the concentrations of any
compound between any pair of groups were identified fol-
lowing p-value adjustment, which included short-chain
fatty acid (SCFA) levels (Figure S9).
A total of 59 level-4 enzyme commission (EC) categories
were differentially abundant between at least one pair of
groups in at least one region of the gut. Notably, there
were significant differences in several EC categories in-
volved in the production of neuroactives (Fig. 7b). Specif-
ically, ileal glutamine--fructose-6-phosphate transaminase
(isomerising) (EC 2.6.1.16) levels, which produces glutam-
ate, was elevated by the administration of both Fr1 (p =
0.002) and UK4 (p = 0.021). In addition, glutamate--am-
monia ligase (EC 6.3.1.2), which produces glutamine, was
higher in the ileum of mice receiving Fr1 (p = 0.024). UK4
increased the prevalence of predicted caecal and faecal
glutamate–cysteine ligase (EC 6.3.2.2) levels (p = 0.038; p
= 0.011 respectively), while caecal tryptophan synthase
(EC 4.2.1.20) was decreased (p = 0.028).
Kefir increases the prevalence of a Lactobacillus reuteri
strain with the potential to produce GABA
Subsequently, changes in the microbiome were explored
in the context of the gut-brain axis by examining the
abundances of gut-brain modules (GBMs) (Fig. 7c),
which are groups of KEGG Orthogroups (KOs) that are
associated with the production of neuroactive com-
pounds [85]. In mice receiving Fr1, caecal “p-Cresol bio-
synthesis” was decreased, while “Quinolinic acid
synthesis” was decreased in the faeces (LDA = 4.43)
compared to milk control. In mice receiving UK4, there
was an increase in ileal “inositol synthesis” (LDA = 4.77)
and “GABA degradation” (LDA=4.70). Finally, the GBM
“GABA synthesis III” was significantly higher in mice re-
ceiving either kefir (Fr1 LDA = 4.39; UK4 LDA = 4.21)
in the faeces. These increases in “GABA synthesis III”
were attributed to L. reuteri, which showed a signifi-
cantly higher prevalence of this GBM compared to milk
controls (Fr1 LDA = 4.20, UK4 LDA = 4.11). Similarly,
the GBM “S-adenosylmethionine synthesis” from P.
goldsteinii was significantly higher in the faeces of mice
receiving Fr1 (LDA = 4.21) and UK4 (LDA = 4.08). Fur-
thermore, the GBM “GABA degradation” from L. reuteri
Fig. 6 Bacterial species in the gastrointestinal microbiota correlate with changes in host immunity and measures of gut serotonin. The prevalence
of bacterial species in the ileum, caecum and faeces were correlated with significantly altered changes in host behaviour and immunity
using HAllA
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was significantly higher in the ileum of mice receiving
UK4 (LDA = 4.16). While “glutamate synthesis I” from
B. pseudolongum was higher in the faeces of Fr1 mice
(LDA = 4.64).
To corroborate the results from HUMAnN2, PanPh-
lAn gene-family matrices were examined to identify
genes associated with the production of neurotransmit-
ters in the detected strains. The detected B. pseudolon-
gum strain encoded two enzymes involved in the
production of glutamate: glutamate synthase and glu-
tamine–fructose-6-phosphate transaminase (isomeris-
ing). Furthermore, this strain also encoded a glutamate/
GABA antiporter, which may be involved in exporting
glutamate from the cell. Similarly, the detected L. reuteri
strain was also found to encode two enzymes associated
with the production of glutamate from glutamine: gluta-
minase and glutamine–fructose-6-phosphate transamin-
ase (isomerising). Importantly, this strain encoded
glutamate decarboxylase, which produces GABA by the
decarboxylation of glutamate, along with a glutamate/
GABA antiporter.
In line with the predicted capacity of L. reuteri to
produce GABA, we observed a negative correlation be-
tween L. reuteri and faecal levels of 2-oxoglutarate (R =
Fig. 7 Kefir modulates the functional capacity of the gastrointestinal microbiota. Beta diversity was assessed by PERMANOVA to investigate the
dissimilarity in the functional capacity of the gut microbiota, which were depicted using MDS plots. Dots represent individual animals (n = 12) (a).
Differential abundances were assessed of enzyme categories (EC) and depicted as violin plots (b). Gut-brain modules (GBMs) were additionally
assessed for their differential abundance (c)
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− 0.474, p = 0.047) and glutamate (R = − 0.420, p = 0.083),
as detected by GC-MS (Fig. 8a). Furthermore, there was a
trend towards a positive correlation between L. reuteri and
succinate levels (R = 0.60, p = 0.100) (Fig. 8a). Furthermore,
faecal succinate levels were increased in mice receiving ke-
fir (Fr1 unadjusted p = 0.037; UK4 unadjusted p = 0.030).
The pattern of correlation suggests that L. reuteri was po-
tentially converting 2-oxoglutarate to glutamate, which was
subsequently converted into GABA, resulting in the pro-
duction of succinate as a by-product. Subsequently, we
employed metabolic modelling using FVA of L. reuteri to
explore this hypothesis in depth. The results indicated that
L. reuteri had the ability to consume 2-oxoglutarate and
glutamate, while it also could secrete GABA and succinate
(Figure 8b).
Discussion
In the present study, we demonstrate that two different
traditionally fermented kefirs differentially affect host be-
haviour and immunity. For instance, Kefir Fr1 increased
reward-seeking behaviour and ameliorated stress-
induced increases in circulating neutrophil and CXCL1
levels. Furthermore, UK4 decreased repetitive behaviour,
increased circulating Treg cells and IL-10 levels, and
ameliorated deficits in reward-seeking behaviour in-
duced by chronic oral gavage stress. In addition, UK4 in-
creased fear-dependent contextual memory, yet
decreased milk gavage-induced improvements in long-
term spatial learning. Both kefirs modulated the com-
position and functional capacity of the microbiota, which
was associated with an increased capacity to produce
GABA. This function was linked to an increased preva-
lence of L. reuteri.
We observed some changes in the gut microbiota that
were specific to kefir Fr1, such as an increase in P. gold-
steinii, B. intestinalis, Anaerotruncus unclassified and P.
goldsteinii. Analysis of GBMs revealed that Fr1 de-
creased the GBM “p-Cresol biosynthesis” and “inositol
synthesis”, while UK4 increased “inositol synthesis”. The
increase in P. goldsteinii abundances were linked to an
increase in the GBM “S-adenosylmethionine synthesis”.
S-adenosylmethionine supplementation has been studied
in numerous randomised, controlled trials involving de-
pressed adults [36, 70]. Notably, one of the key features
of depression is decreased reward-seeking behaviour (i.e.
anhedonia) and that Fr1 increased reward-seeking be-
haviour in the saccharin preference test. As such, the in-
crease in predicted S-adenosylmethionine synthesis
could indicate increased levels of S-adenosylmethionine,
which in turn might have contributed to the Fr1-
induced increase in reward-seeking behaviour. It is im-
portant to note, however, that no changes were observed
in other measures of depressive-like behaviour. Our re-
sults also reveal that Fr1 ameliorated stress-induced defi-
cits in colonic serotonergic signalling, even though it is
important to note that no corresponding serotonin-
related changes were observed in the gut microbiome
and metabolome and that the determined effects were
weak. Furthermore, Fr1 increased circulating neutrophil
and CXCL1 levels. Notably, p-Cresol, of which the pre-
dicted biosynthesis was decreased by Fr1, alters neutro-
phil function in dogs [10]. In addition, Fr1 increased B.
pseudolongum abundances in the ileum, whereas UK4
increased B. pseudolongum abundances in the caecum.
In tandem, ileal B. pseudolongum abundances correlated
with circulating neutrophil levels, indicating that B.
pseudolongum abundances in the ileum specifically,
might contribute to the decrease in neutrophil levels ob-
served in mice receiving Fr1.
Some of the other changes in the composition of the
microbiota were specific to UK4, such as an increased
prevalence of Alistipes unclassified and decreased C.
Fig. 8 The kefir-induced increased Lactobacillus reuteri strain has the potential to produce GABA. Spearman rank correlations between
Lactobacillus reuteri abundances and levels of faecal 2-oxoglutarate, glutamate and succinate were performed (a). Faecal metabolite levels were
quantified using chromatography–mass spectrometry (GC-MS). Flux variability analysis was used to assess whether L. reuteri can influence 2-
oxoglutarate, glutamate and succinate levels (b)
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Arthromitus unclassified. In tandem, UK4 decreased re-
petitive behaviour and modestly increased reward-
seeking behaviour in the female urine sniffing test, also
often used as a measure of depression-related anhedonia.
It is important to note, however, that no changes were
observed in other measures of depressive-like behaviour.
UK4 also decreased milk gavage-induced improvements
in long-term spatial learning, yet increased fear-
dependent contextual memory, indicating that not all
behavioural effects induced by kefir are positive. Finally,
UK4 increased circulating Treg cells and IL-10 levels. In
tandem, ileal C. Arthromitus unclassified abundances
correlated with circulating Treg cell levels, indicating
that this bacterial species is likely contributing to the in-
crease in Treg cell levels induced by UK4. Notably, sup-
plementation of L. kefiri CIDCA 8348 results in
increased gene expression of IL-10 in the ileum and
MLNs in mice [15]. In addition, specific bacterial species
that were increased by kefir administration, such as B.
pseudolongum and L. reuteri, have previously been asso-
ciated with increased levels of the anti-inflammatory
cytokine IL-10 in mice and Treg cells in mice and
humans, respectively [53, 65].
Analysis of the gut microbiota revealed that UK4 in-
creased alpha diversity in the caecum, but no other
changes in alpha diversity were observed in any other re-
gion or comparison. Analysis of beta diversity revealed a
trend towards significant separation induced by both Fr1
and UK4, which resulted in a significant separation in-
duced by kefir overall. Changes in the overall compos-
ition of the gut microbiota induced by kefir, or kefir-
associated bacterial strains have been reported previ-
ously [15, 30, 34, 40, 90]. Notably, none of the bacterial
strains present in the kefir microbiota were detected in
the gut microbiota of mice receiving kefir, indicating
that the kefir microbiota did not colonise to high levels.
This has parallels with the fact that probiotics most fre-
quently do not colonise the gut [21]. Our analysis add-
itionally revealed that both kefirs increased the
prevalence of L. reuteri, E. plexicaudatum, B. pseudolon-
gum, while decreasing of L. bacterium 3_1_46FAA, P.
acnes, and B. amyloliquefaciens. Notably, L. reuteri is a
bacterial strain that has been ascribed numerous benefi-
cial effects on host immunity and metabolism [52, 53].
Notably, previous reports have also demonstrated an in-
creased prevalence of Lactobacillus species in response
to kefir supplementation [40], as well as L. kefiri CIDCA
8348 administration, a species frequently found in kefir
[15].
Our data also reveals that both kefirs significantly
modulated the functional capacity of the gut microbiota
and altered the levels of GBMs, which was related to the
prevalence of specific bacterial strains. Importantly,
kefir-induced increases in L. reuteri levels were linked to
an increased capacity to produce GABA. Indeed, Lacto-
bacillus strains have previously been reported to pro-
duce GABA [6, 7, 46]. Our data additionally reveals that
L. reuteri encodes enzymes and antiporters associated
with GABA production. Furthermore, levels of faecal
metabolites associated with GABA synthesis (i.e. 2-
oxoglutarate, glutamate and succinate) correlate with L.
reuteri abundances. GABA is the primary inhibitory
neurotransmitter in the brain and central GABA levels
have been linked to anxiety and depression [7], indicat-
ing that enhancing GABA production in the gut might
be associated with anxiety- and depressive-like behav-
iour. Indeed, two GABA-producing Lactobacillus strains
have recently been shown to reduce depressive-like be-
haviour in high fat diet-induced obese mice [58]. Various
Lactobacillus strains, or Lactobacillus-containing supple-
ments, have been shown to reduce depressive-like be-
haviour in rodents [1, 13, 23, 44, 45] and improve
measures of depression in humans [3, 5, 39, 76]. Fur-
thermore, abundances of faecal GABA-producers, such
as Bacteroides, correlate negatively with brain signatures
associated with depression [77]. Notably, one of the key
features of depression is decreased reward-seeking be-
haviour (i.e. anhedonia) and that both kefirs increased
reward-seeking behaviour. It is, however, important to
note that it is still unclear whether gut-derived GABA
can cross the blood-brain barrier and whether increasing
gut-derived GABA levels can improve mood [9].
Conclusion
These data demonstrate that kefir can modulate specific
aspects of the microbiota-gut-brain axis in mice, sup-
porting the recent broadening of the definition of psy-
chobiotics to include fermented foods, such as the
fermented milk drink kefir [64]. In addition, both kefirs
differentially affected repetitive behaviour and reward-
associated behaviour. In line with these findings, kefirs
differentially impacted systemic immunity and colonic
serotonergic signalling. Furthermore, kefir influenced
specific gut microbial functional capacities, including the
biosynthesis of various neuroactives such as GABA.
These changes in the gut microbiota function and per-
ipheral immunity might contribute to the kefir-induced
behavioural phenotype, even though more research is
warranted to validate whether these specific microbiota-
gut-brain axis pathways are involved at all. Moreover,
studies on the validation of kefir as a dietary intervention
to improve mood in humans are now warranted.
Methodology
Animals
This study used male C57BL/6j mice (8 weeks of age on
arrival; Envigo, UK; n = 12/group, n = 48 in total).
Treatment groups were divided into 1) (cow’s) Milk
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control, 2) Kefir gavage–Fr1, 3) Kefir gavage UK4, 4) un-
disturbed control. The last group was added to control
for the fact that chronic oral gavage or milk administra-
tion could affect behaviour or physiology [87]. Food and
drinking water were provided ad libitum throughout the
study. Animals were housed in groups of 4. The holding
room had a temperature of 21 ± 1 °C and humidity of 55
± 10% with a 12-h light/dark cycle (lights on at 7:00 am).
Bodyweight was monitored on a weekly basis. Experi-
ments were conducted under the project authorisation li-
cense B100/3774 in accordance with the European
Directive 86/609/EEC and the Recommendation 2007/
526/65/EC and approved by the Animal Experimentation
Ethics Committee of University College Cork. All efforts
were made to reduce the number of animals used and to
minimise the suffering of these animals.
Experimental timeline and behavioural testing
Animals were habituated for 1 week prior to the onset of
daily kefir administration by oral gavage. After 3 weeks of
treatment, animals were assessed for their behavioural
phenotype using various tests, which were formed in order
of least stressful to most stressful to reduce the likelihood
of prior behavioural tests influencing subsequent ones
(Fig. 9). In addition, there was a minimum of 36 h between
tests. The order of testing was as follows: (1) marble bury-
ing test, (2) 3-chamber social interaction test, (3) elevated
plus maze, (4) open-field test, (5) tail-suspension test, (6)
saccharin preference test, (7) female urine sniffing test, (8)
stress-induced hyperthermia test, (9) intestinal motility
test, (10) assessment of faecal water content and weight,
(11) appetitive Y-maze, (12) fear conditioning, (13) forced
swim test. At the end of the study, body composition (i.e.
percentage lean, fat and fluid mass) was assessed (Minis-
pec mq 7.5), after which animals were immediately sacri-
ficed by decapitation.
Kefir culturing and administration
Kefir grains were cultured in Irish whole full fat cow’s
milk (2% w/v) at 25 °C and milk were renewed every 24
h using a sterile Buchner funnel and sterile Duran bottle,
as previously described [25, 88]. Grains were rinsed with
deionised water prior to the renewal of milk. The fer-
mented milk (i.e. kefir) collected after 24-h culturing, or
unfermented milk control, were administered to the
mice within 1 h by oral gavage (0.2 mL). The same milk
was used for the unfermented milk control and was
similar to the kefir, also incubated for 24 h at 25 °C.
Daily kefir administration was performed after the be-
havioural test, if one was performed that day, between
4.00 and 7.00 pm. To analyse the kefir microbiota over
time, aliquots from the kefir administered to the mice
were taken on a weekly basis and stored at –80 °C for
subsequent analysis.
Marble burying test
Mice were tested for repetitive behaviour with the mar-
ble burying test [81], which was conducted as previously
described [14]. Animals were individually placed in a
novel Plexiglas cage (35 × 28 × 18.5 cm, L × W × H),
which was filled with sawdust (5 cm) and had 20 equally
spread marbles placed on top (5 × 4 rows). After mice
had spent 30 min in the cage, the number of buried
marbles was counted by two researchers and averaged.
A buried marble was defined as 2/3 of the marble not
being visible anymore. Sawdust was renewed, and mar-
bles cleaned with 70% ethanol in-between animals.
3-chamber social interaction test
The three-chamber sociability test was used to assess so-
cial preference and recognition and was conducted as
previously described [22]. The testing apparatus was a
three-chambered, rectangular box. The dividing walls
between each chamber (20 × 40 × 22 cm, L × W × H)
had small circular openings (5 cm diameter), allowing
for access to all chambers. The two outer chambers con-
tained wire cup-like cages (10 cm bottom diameter, 13
cm height), allowing for auditory, olfactory and visual,
but not physical contact. The test consisted of three 10-
min phases: (1) habituation, (2) social preference, (3)
Fig. 9 Experimental design. Animals received three weeks of treatment lead in, where animals only received kefir or milk supplementation, after
which they were assessed for their behavioural phenotype. Treatment groups consisted of (1) no gavage control, (2) milk gavage control, (3) kefir
gavage–Fr1, and (4) kefir gavage–UK4 (n = 12/group). The order of behavioural tests was as following: week 4: marble burying test (MB), 3-
chamber social interaction test (3CT) and elevated plus maze (EPM); week 5: open-field test (OF) and tail suspension test (TST); week 6: saccharin
preference test (SPT); week 7: female urine sniffing test (FUST); week 8: stress-induced hyperthermia test (SIH); week 9: intestinal motility test (IM)
and faecal water content assessment (FWC): week 9–12: appetitive Y-maze; week 13: fear conditioning; week 14: forced swim test; week 15:
euthanasia. Postmortem, ileal, caecal and faecal microbiota composition and function were investigated by shotgun sequencing and faecal
metabolomics. Host immunity was assessed using flow cytometry and by quantification of cytokines. Finally, ileum and colonic serotonergic levels
were quantified by high-performance liquid chromatography (HPLC)
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social recognition. In the first phase (habituation), mice
were allowed to explore the entire box with both wire
cup-like cages left empty to allow for habituation to the
novel environment. In the second phase (social prefer-
ence), one wire cup-like cage contained a novel, age-
matched, conspecific, male mouse, whereas the other
cage contained an object (rubber duckie). In the third
phase (social recognition), the mouse of the previous
trial was left in the wire cup-like cage (familiar mouse),
while the object was replaced with a conspecific mouse
(novel mouse). The test mouse was held in the middle
chamber while the conspecific mouse and object were
placed in the cup wire-like cages. The location of the
conspecific mice and object were systemically altered in-
between test mice. The three-chamber test apparatus
and wire cup-like cages were cleaned with 70% ethanol
after each test mouse and left to dry for a few minutes.
To reduce potential anxiogenic factors, all mice were ha-
bituated to the testing room 40 min before the test, the
floor of the testing arena was covered with sawdust and
testing was performed under dim light (60 lux). All ex-
periments were videotaped using a ceiling-mounted
camera and were scored blinded for the time interacted
with the wire cup-like cages. The discrimination index
was calculated as follows: Time spent interacting with
object or mouse/total time spent interacting × 100%.
Elevated plus maze
The elevated plus maze test was used to assess anxiety-
like behaviour and was conducted as previously de-
scribed [14]. The elevated plus maze apparatus was ele-
vated 1 m above the ground and consisted of a grey
cross-shaped maze with two open arms and two closed
arms (50 × 5 cm with 15 cm walls in the closed arms
and 1 cm walls in the open arms). Mice were allowed to
explore the maze for 5 min. Mice were habituated to the
room 30 min prior to the test. Experiments were con-
ducted in red light (5 lux). The elevated plus maze ap-
paratus was cleaned with 70% ethanol in-between
animals. Experiments were videotaped using a ceiling-
mounted camera and videos were scored blinded for
time spent in the open arms, which was defined as all
paws in the open arm.
Open-field test
Mice were assessed for locomotor activity and response
to a novel environment in the open-field test, which was
conducted as previously described [14]. Animals were
placed in an open arena (40 × 32 × 24 cm, L × W × H)
and were allowed to explore the arena for 10 min. Ani-
mals were habituated to the room 30 min prior to the
test. Testing was performed under dim light (60 lux).
The open field test box was cleaned with 70% ethanol
in-between animals. Experiments were videotaped using
a ceiling-mounted camera and were analysed for time
spent in the virtual centre zone (defined as 50% away
from the edges) and total distance travelled using Etho-
vision version 13 software (Noldus).
Tail-suspension test
The tail-suspension test was used to assess depressive-
like behaviour and was conducted as previously de-
scribed [14]. Mice were hung by their tail using adhesive
tape (2 cm from the tip of the tail) to a 30-cm-elevated
grid bar for 6 min. Experiments were videotaped using a
numeric tripod-fixed camera and videos were scored
blinded for the time mice spent immobile.
Saccharin preference test
Mice were assessed for reward-seeking behaviour using
the saccharin preference test as previously conducted
[54]. Mice were first habituated to single housing and
having two drinking water bottles for 3 days. Drinking
water intake and food intake was measured during the
habituation phase of the test. Hereafter, one drinking
water bottle was replaced by one containing a saccharin
solution (0.1% w/v) for 24 h. Drinking water bottles were
weighed every 12 h during the testing phase to calculate
saccharin preference. The side on which the regular
drinking water bottle and the one containing saccharine
solution were randomised and counterbalanced between
groups. During the habituation phase, drinking water
bottles were alternated every 24 h, whereas bottles were
alternated every 12 h during the testing phase. Saccharin
preference was calculated using the following formula:
Total sucrose intake/total fluid intake × 100%.
Female urine sniffing test
Mice were assessed for hedonic and reward-seeking be-
haviour in the female urine sniffing test, which was per-
formed as previously described [28]. Prior to this
experiment, vaginal smears from age-matched female
C57BL/6 mice (n = 20; Envigo, UK) were taken and
assessed for their estrous cycle. Urine from female mice
in the esterus stage was collected and pooled. Male mice
were habituated 45 min before the start of the test to
the test room, with a cotton bulb attached to the lid of
their housing cage. The test mice were subsequently in-
troduced to a new cotton bulb containing 60 μl sterile
water. After a 45-min intertrial-interval, mice were in-
troduced to a new cotton bulb containing 60 μl urine
from a female mouse in esterus for 3 min. The experi-
ment was conducted in red light (5 lux). All tests were
videotaped using a ceiling-mounted camera and inter-
action time with the cotton bulbs was scored blinded.
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Stress-induced hyperthermia test
The stress-induced hyperthermia test was used to assess
stress-responsiveness, which was conducted as previ-
ously described [14]. Body temperature was determined
at baseline (T1) and 15 min later (T2) by gently inserting
a Vaseline-covered thermometer 2.0 cm into the rectum.
The temperature was noted to the nearest 0.1 °C after it
stabilised (~ 10 s). Mice were restrained by scruffing
during this procedure which was the stressor. Animals
were habituated to the testing room 1 h prior to the test.
The difference between T1 and T2 reflected the stress-
induced hyperthermia.
Appetitive Y-maze
The appetitive Y-maze was used to assess long-term
spatial learning and was performed as previously de-
scribed [27]. The test consisted of two phases; the initial
learning phase, where the first association between the
location of the food reward and spatial reference cues
were formed, and the reversal learning phase, where the
location of the food reward was altered in reference to
the spatial reference cues, in which the relearning of a
context was measured.
The Y-maze apparatus was elevated 80 cm above the
ground and consisted of three arms (50 × 9.5 cm, L ×
W, with a 0.5-cm-high rim) arranged at an angle of 120°
of each other (Figure S10A). The apparatus could be ro-
tated during testing. A small plastic food well (a cap of a
15-mL tube) was placed at the distal end of each arm.
Testing was performed under dim light (30 lux).
Prior to testing, mice were food-restricted (3–4 g food
per day) and kept between 90 and 95% of their free-
feeding body weight (Figure S10B). Two days later, ani-
mals were habituated in their home cage to the small
plastic well containing 1 mL food reward (sweetened
condensed milk diluted in water 1:1) per mouse before
the onset of the active phase. Mice were subsequently
habituated on the Y-maze apparatus in home cage
groups until mice were freely running around and read-
ily collecting the food reward (each arm contained 1 mL
food reward), which took 2 days. Finally, mice were indi-
vidually placed on the Y-maze until they were running
and collected the food reward (each arm contained 0.1
mL food reward), which took 4 days.
During the first phase (Initial learning), mice were
assigned a goal arm according to the position in the
room, which was counter-balance between groups. The
maze was rotated 120° every trial to prevent potential as-
sociations of the correct goal arm with the texture or
smell of the arm. The starting position for each trial was
determined by a pseudorandomised computer sequence,
which was different for each mouse but was the same
across treatment groups. This sequence did not contain
more than three consecutive starts in the same position
to avoid temporary position preferences. Animals were
tested in groups of eight, with four animals per two ex-
perimental group (i.e. two home cages). Each mouse re-
ceived ten trials per day with an intertrial interval of
approximately 10 min. The time of testing was counter-
balanced between groups and rotated each day to reduce
the effect of testing during a specific time of the day.
Mice received eight consecutive days of initial learning,
resulting in a total of 80 trials. During the second phase
(reversal learning), the goal arm was changed to a differ-
ent arm, and the placement of the mice was changed ac-
cordingly. This phase lasted 5 days, resulting in a total of
50 trials.
For each trial, the food well on the goal arm was filled
with 0.1 mL food reward (sweetened condensed milk di-
luted in water 1:1). The mouse was placed at the end of
the start arm and was allowed to run freely on the maze.
The entries into each arm were counted, as well as when
the mouse went into the goal arm immediately, of which
the latter was counted as a successful trial. The mouse
was placed back into the home cage after it consumed
the food reward. In the rare occasion that the mouse did
not walk into the goal arm and collect the food reward
within 90 s, then the mouse was gently guided towards
the goal arm and given a chance to collect the food re-
ward, after which it was also returned to the home cage.
A trial where the mouse did not walk into any arm was
excluded from the analysis, as this indicates that the
mouse was anxious. An entry was counted when the tail
of the animal passed the entry of the arm. Between mice,
the food wells were not cleaned so that a slight odour of
milk reward remained at all times, ensuring mice found
the goal arm based on spatial cues, rather the olfactory
cues.
Fear conditioning
Fear conditioning was used to assess amygdala-
dependent learning memory and was conducted as pre-
viously described [35]. The test consisted of 3 days/
phases: (1) training, (2) assessment of cued memory, (3)
assessment of contextual memory, each of which was
carried on successive days with a 24-h interval. In phase
1 (training), animals were recorded for 3 min (baseline),
followed by 6 tone-conditioned stimuli (70 dB, 20 s),
followed by a foot shock (0.6 mA, 2 s), with a 1-min
interval. In phase 2 (assessment of cued memory), mice
were placed in a novel context (i.e. black-checkered walls
with a solid Plexiglas opaque floor, under which paper
was placed containing a 400 μl vanilla solution (79.5%
water/19.5% ethanol/1% vanilla-extract solution), and
after an initial acclimation period of 2 min, mice re-
ceived 40 presentations of the tone-conditioned stimuli,
each lasting 30 s with a 5-s interval. In phase 3 (assess-
ment of contextual memory), mice were placed in the
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context of day 1 and recorded for 5 min, without the
presentation of any tone-conditioned stimuli. The fear
conditioning apparatus was cleaned with 70% ethanol
in-between animals.
Forced swim test
The forced swim test was used to assess depressive-like
behaviour and was conducted as previously described
[19]. Mice were individually placed in a transparent glass
cylinder (24 × 21 cm diameter) containing 15-cm-depth
water (23–25 °C) for 6 min. Mice were gently dried after
the test, and water was renewed after each animal. Ex-
periments were videotaped using a ceiling-mounted
camera and videos were scored blinded for immobility
time in the last 4 min of the test.
Repeated plasma sampling for corticosterone
quantification
Plasma from each animal was sampled by tail-tip 5 min
before the forced swim test, and repeatedly after the test
in 30 min intervals up to 120 min, as previously dis-
cussed [14]. For the tail-tip, the end of the tail was gently
held with two fingers without restraining the mouse.
Using a single edge razor blade, a 2–4 mm long diagonal
incision was made at the end of the tail. Approximately,
40 μl of whole blood was taken per time point using an
EDTA-containing capillary (Fisher Scientific, 749311),
deposited in an Eppendorf and centrifuged for 10 min at
3500×g at 4 °C. Plasma was collected and stored at −80
°C for later corticosterone quantification.
Intestinal motility assay
Gastrointestinal motility was assessed as previously de-
scribed [31]. Briefly, mice were singly housed at 8.00 am.
with ad libitum access to food and drinking water.
Three hours later, 0.2 mL of non-absorbable 6% carmine
red in 0.5% methylcellulose dissolved in sterile
phosphate-buffered saline was administered by oral gav-
age, after which drinking water was removed. The la-
tency for the excretion of the first red-coloured faecal
pellet was subsequently timed as a measure of gastro-
intestinal motility.
Assessment of faecal water content and weight
Mice were singly housed for 1 h during which faecal pel-
lets were collected (± 9 per animal). Pellets were subse-
quently weighed, dried at 50 °C for 24 h and weighed
again. The average weight per pellet and percentage of
faecal water content was calculated.
Tissue collection
Collection of faecal samples for metabolomics was done
one week prior to euthanasia. This was done by single
housing mice until 2 pellets were dropped between
10.00 and 12.00 am. The order of faecal pellet collection
was counterbalanced between groups to minimise the ef-
fect of circadian rhythm. Pellets were snap-frozen on dry
ice within 3 min after excretion and subsequently stored
at −80 °C.
Animals were sacrificed by decapitation in a random
fashion regarding test groups between 9.00 am and 2.00
pm. Trunk blood was collected in 3 mL EDTA-
containing tubes (Greiner bio-one, 454086) and 100 μl
was put in a separate Eppendorf for flow cytometry.
Both tubes were centrifuged for 10 min at 3500×g at 4
°C, after which plasma was collected and stored at –80
°C for cytokine quantification. The remaining cell pellet
of the Eppendorf containing 100 μl blood was stored on
ice and subsequently used for flow cytometry. Mesen-
teric lymph nodes (MLNs) were extracted, fat tissue was
removed and stored in RPMI-1640 medium with L-glu-
tamine and sodium bicarbonate (R8758, Sigma), supple-
mented with 10% FBS (F7524l, Sigma) and 1% Pen/strep
(P4333, Sigma) on ice for subsequent flow cytometry.
The faecal pellets, caecum, and contents of the distal
part of the ileum (2 cm) were collected, snap-frozen on
dry ice and stored at –80 °C for shotgun sequencing.
Flow cytometry
Blood and MLNs collected when animals were sacrificed
were processed on the same day for flow cytometry, as
previously described [8, 32]. Blood was resuspended in
10 mL home-made red blood cell lysis buffer (15.5 mM
NH4Cl, 1.2 mM NaHCO3, 0.01 mM tetrasodium EDTA
diluted in deionised water) for 3 min. Blood samples
were subsequently centrifuged (1500×g, 5 min), split into
2 aliquots and resuspended in 45 μl staining buffer
(autoMACS Rinsing Solution (Miltenyi, 130-091-222)
supplemented with MACS BSA stock solution (Miltenyi,
130-091-376)) for the staining procedure. MLNs were
poured over a 70 μm strainer and disassembled using
the plunger of a 1-mL syringe. The strainer was subse-
quently washed with 10 mL media (RPMI-1640 medium
with L-glutamine and sodium bicarbonate, supplemented
with 10% FBS and 1% Pen/strep), centrifuged and 2 ×
106 cells were resuspended in 90 μl staining buffer and
split into two aliquots for the staining procedure. For
the staining procedure, 5 μl of FcR blocking reagent
(Miltenyi, 130-092-575) was added to each sample. Sam-
ples were subsequently incubated with a mix of anti-
bodies (Blood aliquot 1; 5 μl CD11b-VioBright FITC
(Miltenyi, 130-109-290), 5 μl LY6C-PE (Miltenyi, 130-
102-391), 0.3 μl CX3CR1-PerCP-Cyanine5.5 (Biolegend,
149010) and 5 μl CCR2-APC (Miltenyi, 130-108-723);
Blood aliquot 2 and MLNs 1; 1 μl CD4-FITC (Thermo-
Fisher, 11-0042-82) and 1 μl CD25-PerCP-Cyanine5.5
(ThermoFisher, 45-0251-80); MLNs 2; 5 μl CD103-FITC
(Miltenyi, 130-102-479), 2 μl CD11c-PE (Miltenyi, 130-
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110-838), 0.3 μl CX3CR1-PerCP-Cyanine5.5 (Biolegend,
149010) and 5 μl MHC-II-APC (Miltenyi, 130-102-139))
and incubated for 30 min on ice. Blood aliquot 1 was
subsequently fixed in 4% PFA for 30 min on ice, whilst
Blood aliquot 2 and MLNs underwent intracellular stain-
ing using the eBioscience™ Foxp3/Transcription Factor
Staining Buffer Set (ThermoFisher, 00-5523-00), according
to the manufacturers’ instructions, using antibodies for
intracellular staining (2 μl FoxP3-APC (ThermoFisher, 17-
5773-82) and 5 μl Helios-PE (ThermoFisher, 12-9883-
42)). Fixed samples were resuspended in staining buffer
and analysed the subsequent day on the BD FACSCalibur
flow cytometry machine. Data were analysed using FlowJo
(version 10), see Figure S11 for the gating information.
Cell populations were selected as following: Treg cells:
CD4+, CD25+, FoxP3+; Neutrophils: CD11b+, LY6Cmid.
SSChigh; Monocytes: CD11b+, LY6Chigh; CD103+ Den-
dritic cells; MHC-II+, CD11c+, CD103+. The investigated
cell populations were normalised to PBMC levels.
Plasma corticosterone and cytokine assessment
Corticosterone quantification of plasma samples (20 μl)
obtained in the forced swim test was performed using a
corticosterone ELISA (Enzo Life Sciences, ADI-901-097)
according to the manufacturer’s guidelines. A multi-
mode plate reader (Synergy HT, BioTek Instruments)
was used to measure light absorbance. Cytokine levels
from plasma samples collected during euthanasia were
quantified using the V-PLEX Proinflammatory Panel 1
Mouse Kit (MSD, K15048D). Cytokine quantification
was done according to the manufacturer’s guidelines
with one modification, where 20 μl plasma sample was
added onto the plate and incubated overnight (15 h) at 4
°C, after which the rest of the protocol was carried out
as suggested by the guidelines. Values under the fit curve
range and detection range were excluded.
High-performance liquid chromatography
5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic
acid (5-HIAA) concentrations were determined using
HPLC based on methodology previously described [16].
Briefly, mobile phase consisted of HPLC-grade 0.1 M
citric acid, 0.1 M sodium dihydrogen phosphate mono-
hydrate, 0.01 mM EDTA disodium salt (Alkem/Reage-
con), 5.6 mM octane-1-sulphonic acid (Sigma Aldrich),
and 9% (v/v) methanol (Alkem/Reagecon). The pH of
the mobile phase was adjusted to 2.8 using 4 N sodium
hydroxide (Alkem/Reagecon). Homogenisation buffer
consisted of mobile phase with the addition of 20 ng/20
μl of the internal standard, N-methyl 5-HT (Sigma Al-
drich). Briefly, tissue samples were sonicated (Sonopuls
HD 2070) for 4 s in 500 μl cold homogenisation buffer
during which they were kept chilled. Tissue homoge-
nates were then centrifuged at 14,000×g for 20 min at 4
°C. The supernatant was collected and the pellet was dis-
carded. The supernatant was then briefly vortexed and
30 μl of supernatant was spiked into 270 μl of mobile
phase. Twenty microliters of the 1:10 dilution was
injected into the HPLC system (Shimadzu, Japan) which
was comprised of a SCL 10-Avp system controller, LC-
10AS pump, SIL-10A autoinjector, CTO-10A oven,
LECD 6A electrochemical detector, and Class VP-5 soft-
ware. The chromatographic conditions were flow rate of
0.9 mL/min using a Kinetex 2.6 u C18 100 A × 4.6 mm
column (Phenomenex), oven temperature of 30 °C, and
detector settings of + 0.8 V. 5-HT and 5-HIAA external
standards (Sigma Aldrich, H7752 and H8876, respect-
ively) were injected at regular intervals during sample
analyses. Monoamines in unknown samples were deter-
mined by their retention times compared to external
standards. Peak heights of the analyte: internal standard
ratio were measured and compared with external stan-
dards, results were expressed as microgram of neuro-
transmitter per gram of tissue.
DNA extractions and sequencing
For analysis of the kefir microbiome, DNA was extracted
from the fermented milk using the PowerSoil DNA Iso-
lation Kit, as described previously [88]. For analysis of
the murine gut microbiome, DNA was extracted from
the total ileal contents, caecal contents and faecal pellets
using the QIAamp PowerFaecal DNA Kit. Whole-
metagenome shotgun libraries were prepared using the
Nextera XT kit in accordance with the Nextera XT
DNA Library Preparation Guide from Illumina, with the
exception that tagmentation time was increased to 7
min. Kefir libraries were sequenced on the Illumina
MiSeq sequencing platform with a 2 × 300 cycles v3 kit.
Gut libraries were sequenced on the Illumina NextSeq
500 with a NextSeq 500/550 High Output Reagent Kit
v2 (300 cycles). All sequencing was performed at the
Teagasc sequencing facility in accordance with standard
Illumina protocols.
Faecal metabolomics
The faecal metabolome was analysed by chromatog-
raphy–mass spectrometry (GC-MS) by MS-Omics,
Copenhagen. Samples were derivatized using methyl
chloroformate. For SCFA quantification, samples were
acidified with hydrochloric acid.
Bioinformatics
Murine reads were removed from the raw sequencing
files using the NCBI Best Match Tagger (BMTagger)
(ftp://ftp.ncbi.nlm.nih.gov/pub/agarwala/bmtagger/), and
fastq files were converted to unaligned bam files using
SAMtools [43]. Duplicate reads were subsequently re-
moved using Picard Tools (https://github.com/
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broadinstitute/picard). Next, low-quality reads were re-
moved using the trimBWAstyle.usingBam.pl script from
the Bioinformatics Core at UC Davis Genome Center
(https://github.com/genome/genome/blob/master/lib/
perl/Genome/Site/TGI/Hmp/HmpSraProcess/trimB-
WAstyle.usingBam.pl). Specifically, MiSeq reads were fil-
tered to 200 bp, while NextSeq were filtered to 105 bp.
All reads with a quality score less than Q30 were dis-
carded. The resulting fastq files were then converted to
fasta files using the fq2fa option from IDBA-UD [59].
Compositional analysis was performed using MetaPh-
lAn2 [83]. Strain-level metagenomic analysis was performed
using StrainPhlAn [84] and PanPhlAn [66] StrainPhlAn
outputs were visualised using GraPhlAn [4]. Custom
PanPhlAn databases were constructed from complete gen-
ome assemblies which were annotated using Prokka [67].
See Table S1 for the list of reference genomes used in this
study. Functional analysis was performed with HUMAnN2
[2], using the bypass-translated-search option, and PanPh-
lAn. HUMAnN2 gene families were mapped to level-4 en-
zyme commission (EC) categories using HUMAnN2 utility
mapping files. Sequence data have been deposited in the
European Nucleotide Archive (ENA). Correlations between
gut microbial species and significantly altered behavioural
and immunological parameters were investigated using
HAllA (https://bitbucket.org/biobakery/halla/wiki/Home).
Analysis of GBMs was performed as previously de-
scribed [85]. Briefly, the UniRef gene families that were
detected by HUMAnN2 were mapped to KEGG
Orthogroups (KOs) using the humann2_regroup_table
function, and the abundances of KOs were normalised
using the humann2_renorm_table function. Next, these
KOs were further mapped to GBMs using Omixer-RPM.
Metagenome co-assembly was performed using
MEGAHIT [42]. MetaBAT 2 [37] was used to recover
genomes from the metagenome. CheckM [57] was used
to assess the quality of the MAGs. The Lactobacillus
reuteri genome was identified using PhyloPhlAn [68].
Prokka was used to annotate the genome and CarveMe
[49] was used to construct a metabolic model. COBR-
Apy [26] was used to perform flux variability analysis
(FVA), with an objective of 95% biomass, of this model.
Raw microbiota reads have been deposited to the
European Nucleotide Archive under the project acces-
sion number PRJEB35751.
Statistical analysis
All behavioural and physiological data were assessed for
normality using the Shapiro-Wilk test and Levene’s test
for equality of variances. The effect of kefir was deter-
mined by a one-way ANOVA, followed by Dunnett’s
post hoc test whenever data were normally distributed.
If data were non-parametrically distributed, then a
Kruskal-Wallis test followed by a Mann-Whitney U test
was used. Undisturbed control and milk control datasets
were assessed for statistical significance using an un-
paired Student’s t test or a Mann-Whitney U test to in-
vestigate the impact of milk gavage. Bodyweight, fear
conditioning and appetitive Y-maze data were assessed
using repeated-measures ANOVA, followed by a Dun-
nett’s post hoc test. The presence of social preference
and recognition in the 3-chamber sociability test was
assessed using a paired Student’s t test. Parametric data
are depicted as bar graphs with points as individual data
points and expressed as mean ± SEM. Non-parametric
data is depicted as a box with whiskers plot. Statistical
analysis was performed using SPSS software version 24
(IBM Corp). A p value < 0.05 was deemed significant
Statistical analysis for bioinformatics data was per-
formed using the R package vegan for alpha diversity
analysis and principal component analysis [56]. The Wil-
coxon rank-sum test was used to measure statistical dif-
ferences in alpha diversity between groups. The adonis
function from vegan was used for PERMANOVA. The
linear discriminant analysis (LDA) effect size (LEfSe)
method [69] was used to investigate if any taxa or
HUMAnN2 pathways were differentially abundant be-
tween groups. Data were visualised using hclust2
(https://bitbucket.org/nsegata/hclust2), GraPhlAn, and
the R package ggplot2 [89].
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